Lifestyle Changes, a Mushroom Supplement and Bupropion for Overweight and Obesity
Tests lifestyle changes, a mushroom supplement and bupropion in overweight adults.
Plain-language title generated from the registry record
Registry title: Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk
Key facts
- Where
- Uppsala and Vaenersborg, SwedenSee the 3 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07806279, who can take part
Where in Sweden
- Region UppsalaUppsala, SwedenNot yet recruiting
- Uppsala University HospitalUppsala, SwedenNot yet recruiting
- Vaestra GoetalandsregionenVaenersborg, SwedenNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Uppsala University
- Trial code
- NCT07806279EU 2026-527136-13-00
- Record updated
- 8 September 2026
- Original description
The increasing prevalence of obesity, its serious health consequences, and the substantial economic burden on healthcare systems underscore a pressing need for effective, long-term prevention strategies that can be implemented in primary care. Emerging evidence suggests that combining lifestyle modification with dietary supplements and pharmacological treatment may enhance and prolong intervention effects, yet comparative long-term data on their individual and combined efficacy are limited. Therefore, this study aims to evaluate the independent and additional effects of a comprehensive lifestyle intervention, a mushroom-based dietary supplement, and bupropion treatment over 12 months, to identify more effective and sustainable strategies for obesity prevention in overweight and obese adults.Read full original descriptionShow less
A 52-week Multicenter, Randomized, Parallel-group Trial in Overweight People Investigating Lifestyle Changes, Mushroom Supplementation and Bupropion to Reduce Adiposity and Cardiometabolic Risk
The increasing prevalence of obesity, its serious health consequences, and the substantial economic burden on healthcare systems underscore a pressing need for effective, long-term prevention strategies that can be implemented in primary care. Emerging evidence suggests that combining lifestyle modification with dietary supplements and pharmacological treatment may enhance and prolong intervention effects, yet comparative long-term data on their individual and combined efficacy are limited. Therefore, this study aims to evaluate the independent and additional effects of a comprehensive lifestyle intervention, a mushroom-based dietary supplement, and bupropion treatment over 12 months, to identify more effective and sustainable strategies for obesity prevention in overweight and obese adults.
Inclusion: Men and women aged 18-55 years; BMI of 25.0 - 34.9 kg/m2; Signed informed consent; Have a mobile phone, tablet, or computer with internet access; Cardiometabolic risk factors: a) None of the following diagnoses: hypertension, hyperlipidemia, or prediabetes according to WHO classification (Stratum A); b) One or several of the following diagnoses: hypertension, hyperlipidemia, or prediabetes according to WHO classification (Stratum B); For women of childbearing potential: use of a highly effective birth control method.
Exclusion: Previous or planned bariatric surgery; Present food intolerances and/or allergies of relevance to the interventions, such as celiac disease and allergy to edible mushrooms or fungal spores; Contraindication to bupropion, or any unacceptable risk with either treatment as assessed by the investigator. Specifically, and not covered elsewhere:; History of epilepsy or lowered seizure threshold; History of bulimia or anorexia nervosa; Central nervous system tumor; Hypersensitivity to bupropion; History of bipolar disorder; Known or suspected Brugada syndrome; Any condition, as judged by the investigator, that suggests that the participant will be non-compliant or otherwise unsuitable to study medication or study participation. For example, serious psychiatric, eating, alcohol or substance abuse disorders; Diagnosed diabetes, coronary heart disease, heart failure, stroke, liver failure or kidney disease (eGFR<60 ml/min/1.73m2) as well as other ongoing serious conditions with short life expectancy or conditions affecting participation in the study; Use of the following medications within indicated time frames:; Other bupropion-containing products (last 2 weeks); Other weight lowering-drugs: orlistat, phentermine-topiramate, sodium-glucose transporter 2 inhibitors (SGLT2i), GLP-1 receptor agonists (last 3 months); Antipsychotics, mirtazapine, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (last 3 months); MAOIs (last 2 weeks); Systemic glucocorticoids (last 3 months); Testosterone, anabolic steroids (last 6 months); Medications not listed above that are metabolized by CYP2D6; Medications that affect CYP2B6; Current or recent adherence to a low-calorie diet, receipt of pharmacological treatment for weight loss, and/or weight loss of > 3 kg within the past 3 months; Be pregnant or intend to become pregnant during the study period; Involvement in the planning and/or conduct of the study; Ongoing participation in another interventional clinical trial.